Evidence map›Paper›PMID 31825979›Full record

ArticlePloS one2019

CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases.

Gina K Thomson, Sameh AbdelGhani, Kenneth S Thomson

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Deceiving Phenotypic Susceptibility Results on aFrontiers in cellular and infection microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gina K ThomsonUniversity of Louisville Hospital, Microbiology Department, Louisville, Kentucky, United States of America.
Sameh AbdelGhaniUniversity of Louisville School of Medicine, Department of Pathology and Laboratory Medicine Louisville, Kentucky, United States of America.
Kenneth S ThomsonUniversity of Louisville School of Medicine, Department of Pathology and Laboratory Medicine Louisville, Kentucky, United States of America.ORCID 0000-0002-7542-2019

Funding

The ExCITE Program: Expediting Commercialization, Innovation, Translation, & EntrepreneurshipU01HL127518 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BATES, PAULA J., MILLER, DONALD M. · 2015 to 2017
$3.0M
NHLBI NIH HHS U01 HL127518
6 · The paper itself

Abstract

Carbapenemase-producing organisms (CPOs) are Gram-negative bacteria that are typically resistant to most or all antibiotics and are responsible for a global pandemic of high mortality. Rapid, accurate detection of CPOs and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified for isolates that produced a single carbapenemase. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C, the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesEnterobacteriaceaeEnzyme AssaysHumansMicrobial Sensitivity TestsPhenotypePseudomonas aeruginosaAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasescarbapenemase

Identifiers

PMID31825979
PMCPMC6905549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.